This has just surfaced today, GlaxoSmithKline plc and Pfizer inc plan to combine their HIV-drug units into a new company that will control almost 20 percent of the market for anti-HIV drugs. The ownership split will be 85/15 in favour of GSK. The final ownership ratios will vary depending upon the outcome of products in development. This is a symptom of the poor outlook for both these companies in this area, with GSK’s Combivir loosing patent protection in 2012, and Pfizer is rumoured to be looking at exiting this entire area. This deal is expected to have a detrimental impact on GSK’s cash flow for the coming financial year so it remains to be seen how the markets will react to it, it looks more like a buy out by GSK than a merger in thsi authors opinion, nothing wrong with that though.
The company will have 11 of agents on the market including Combivir and Epzicom (with combined sales of approximalty GBP £1.51bn (US$2.25bn), and Pfizer’s Selzentry will be boosted by access to the GSK’s HIV marketing infrastructure. The company will have an estimated 17 product in its development pipeline, four of which are in phase 2 development. it should be in a strong position in the area but this author wonders about risk loading an organisation around a single (high risk) indication.
If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com
Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug evelopment target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
For Assistance with Regulatory Planning and Exicution of Clinical Trials Click Here
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!
Fill Out the Short Form Below… |
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Pingback: I was considering to buy a foreclosure house. The price is good but the house has no cooling system? | How Does Foreclosure Work